Durect Corporation

Atrix Laboratories, Inc.

Southern Biosystems, Inc.

Vipont Pharmaceutical, Inc.

Surmodics, Inc.

Evonik Corporation

Surmodics Pharmaceuticals, Inc.

Surmodics Smp, Inc.

Richard J. Holl

John W. Gibson

Arthur J. Tipton

Stacey Meador

Arthur J Tipton

John W Gibson

Richard L Dunn

John Middleton

Su Il Yum

Grant Schoenhard

Michael S Zamloot

Roger Fu

Richard J Holl

Jack A Rogers

George L Southard

Ronald J Harkrader

Gerald L Yewey

Shawn M Fujita

Nancy L Krinick

Gerbrand Brouwer

Michael L Radomsky

John C Middleton

Kevin Burton

Kenneth C Godowski

Thomas R Tice

Richard L Norton

Thomas C Bischoff

Danielle L Biggs

Jay K Staas

Peter Markland

Bruce W Hudson

Howard Bowman

William Ferris

Patrick J Burns

Stacey S Miller

Stacey A Sullivan

Stephen Michael Knight

Kevin W Burton

Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Oral drug delivery system

Described herein are implantable composites, articles comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.

Implantable composites and implants comprising same

Described herein are implantable composites, kits comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.

Elastic implantable composites and implants comprising same

A coaxial implant has been developed using biodegradable polymeric materials. The coaxial implant has a core containing drug, surrounded by a semi-permeable membrane that controls the rate of release of material from the core. The core containing the drug and the polymer membrane(s) can be the same or different polymer. The core acts as a reservoir of drug, which partitions from the core polymer to form a saturated solution of drug at the polymer membrane.

Zero-order prolonged release coaxial implants

Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject.

Polymeric device for controlled release of active agents

Polymeric devices for controlled release of active agents

Described herein are methods for reducing and achieving the desired release of an agent from a delivery system. The desired release kinetics are achieved by exposing the surface of the delivery system with a fluid for a desired period of time.

Methods for manufacturing delivery devices and devices thereof

A coaxial implant has been developed using entirely biodegradable polymeric materials. As referred to herein, a coaxial implant is a device having a core containing drug, surrounded by a semi-permeable membrane that controls the rate of release of material from the core. The device is formed by extrusion, using a pre-milling and extruding step to maximize uniformity of drug dispersion within the polymeric material. In one embodiment, the polymer is processed to yield a semi-crystalline polymer, rather than an amorphous polymer. The core containing the drug and the polymer membrane(s) can be the same or different polymer. The polymer can be the same or different composition (i.e., both polycaprolactone, or both poly(lactide-co-glycolide) of different monomer ratios, or polycaprolactone outside of a core of poly(lactide)), of the same or different molecular weights, and of the same or different chemical structure (i.e., crystalline, semi-crystalline or amorphous). The core acts as a reservoir of drug, which partitions from the core polymer to form a saturated solution of at least 10% drug at the polymer membrane.

Growing community of inventors

Birmingham, AL, United States of America

Arthur J Tipton